Evidence map›Paper›PMID 41198981›Full record

ArticleCommunications biology2025

A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomes.

Tashinga E Bapiro, Scott Martin, Thomas S Blacker, Stephen D Wilkinson, Alexandra L Orton, Niresh Hariparsad, Rhys D O Jones, Michael R Duchen, Stephanie Harlfinger

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tashinga E BapiroDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, UK. tashinga.bapiro1@astrazeneca.com.ORCID http://orcid.org/0000-0002-1483-2161
Scott MartinDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, UK.
Thomas S BlackerResearch Department of Cell & Developmental Biology, University College London, London, UK.ORCID http://orcid.org/0000-0002-8949-6238
Stephen D WilkinsonDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, UK.
Alexandra L OrtonDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0002-5440-6802
Niresh HariparsadDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, 35 Gatehouse Park Drive, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6290-5329
Rhys D O JonesDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, UK.
Michael R DuchenResearch Department of Cell & Developmental Biology, University College London, London, UK.ORCID http://orcid.org/0000-0003-2548-4294
Stephanie HarlfingerDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NADPH-P450 oxidoreductase (POR) is the accepted redox-partner for drug-metabolising cytochrome P450s (CYPs) over NADH-cytochrome b

Indexed as

Cytochrome P-450 Enzyme SystemHepatocytesMicrosomes, LiverCytochrome-B(5) ReductaseCytochrome P-450 CYP3AHumansMidazolamNADPOxidation-ReductionCYP3A4 protein, humanCytochrome-B(5) ReductaseCytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemMidazolamNADP

Identifiers

PMID41198981
PMCPMC12592420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.